Cargando…

Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment

Dermatomyositis (DM) classically presents as a dyad of typical cutaneous findings and varying degrees of proximal muscle weakness. Interestingly, the development of DM may signal underlying malignancy, and numerous myositis-specific autoantibodies have been associated with this paraneoplastic phenom...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerman, Irina, Richardson, Christopher T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825482/
https://www.ncbi.nlm.nih.gov/pubmed/31723534
http://dx.doi.org/10.7759/cureus.5775
_version_ 1783464910420705280
author Lerman, Irina
Richardson, Christopher T
author_facet Lerman, Irina
Richardson, Christopher T
author_sort Lerman, Irina
collection PubMed
description Dermatomyositis (DM) classically presents as a dyad of typical cutaneous findings and varying degrees of proximal muscle weakness. Interestingly, the development of DM may signal underlying malignancy, and numerous myositis-specific autoantibodies have been associated with this paraneoplastic phenomenon. Positivity for anti-TIF1gamma antibody, in particular, raises suspicion for cancer-associated DM. Here, we present an unusual case of anti-TIF1gamma antibody-positive DM that ultimately lead to the diagnosis of myelodysplastic syndrome (MDS). Importantly, topical treatment and chemotherapy targeting MDS resulted in a swift and remarkable amelioration of cutaneous disease.
format Online
Article
Text
id pubmed-6825482
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-68254822019-11-13 Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment Lerman, Irina Richardson, Christopher T Cureus Rheumatology Dermatomyositis (DM) classically presents as a dyad of typical cutaneous findings and varying degrees of proximal muscle weakness. Interestingly, the development of DM may signal underlying malignancy, and numerous myositis-specific autoantibodies have been associated with this paraneoplastic phenomenon. Positivity for anti-TIF1gamma antibody, in particular, raises suspicion for cancer-associated DM. Here, we present an unusual case of anti-TIF1gamma antibody-positive DM that ultimately lead to the diagnosis of myelodysplastic syndrome (MDS). Importantly, topical treatment and chemotherapy targeting MDS resulted in a swift and remarkable amelioration of cutaneous disease. Cureus 2019-09-26 /pmc/articles/PMC6825482/ /pubmed/31723534 http://dx.doi.org/10.7759/cureus.5775 Text en Copyright © 2019, Lerman et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Rheumatology
Lerman, Irina
Richardson, Christopher T
Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title_full Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title_fullStr Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title_full_unstemmed Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title_short Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment
title_sort anti-tif1gamma antibody-positive dermatomyositis associated with myelodysplastic syndrome: response to treatment
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825482/
https://www.ncbi.nlm.nih.gov/pubmed/31723534
http://dx.doi.org/10.7759/cureus.5775
work_keys_str_mv AT lermanirina antitif1gammaantibodypositivedermatomyositisassociatedwithmyelodysplasticsyndromeresponsetotreatment
AT richardsonchristophert antitif1gammaantibodypositivedermatomyositisassociatedwithmyelodysplasticsyndromeresponsetotreatment